Interceptor Tab 23mg 23 mg Tablet is a Health Canada–registered veterinary drug (DIN 00846457) held by Ciba-Geigy Canada Ltd, Animal Health Division, containing Milbemycin Oxime. Health Canada lists its status as Cancelled Post Market (status date 07 Aug 1997). Nexara Health has matched 10 registrations of Milbemycin Oxime across 1 other regulated market.
Health Canada registration
| DIN | 00846457 |
|---|---|
| Brand name | Interceptor Tab 23mg |
| Active ingredient | Milbemycin Oxime |
| Strength | 23 mg |
| Dosage form | Tablet |
| Route | Oral |
| Company | Ciba-Geigy Canada Ltd, Animal Health Division |
| Status | Cancelled Post Market — 07 Aug 1997 |
| Class | Veterinary |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Milbemycin Oxime registered in other markets
10 registrations of the same molecule in 1 national registry outside Canada (first 8 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | Milbemycin Oxime | Zhejiang Hisun Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Hubei Honch Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd. | Powder | FDA NDC |
See every manufacturer of Milbemycin Oxime worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Interceptor Tab 23mg (DIN 00846457) marketed in Canada?
No. Health Canada lists DIN 00846457 as Cancelled Post Market as of 07 Aug 1997.
Who holds the Canadian licence for this product?
Ciba-Geigy Canada Ltd, Animal Health Division is the company of record in the Health Canada Drug Product Database.
Is Milbemycin Oxime registered outside Canada?
Yes — Nexara Health has matched 10 registrations in 1 other market (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 00846457, status date 1997-08-07; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 00846457, status date 1997-08-07; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 00846457, status date 1997-08-07; national medicine registries: FDA NDC. Last reviewed 2026-09-17. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.